Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared 12% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker.

Q4 2024 Earnings Conference Call February 6, 2025 2:00 AM ETCompany ParticipantsRonojoy Banerjee - Communications ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

AMD is shipping more desktop chips to keep up with the demand as the Ryzen 9800X3D remains hard to find in stock.

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...